Answers are grounded in this paper and cite their sources.
Biotin–thiamin–responsive basal ganglia disease or biotin–thiamin–responsive encephalopathy type 2 is a rare treatable autosomal recessive neurometabolic disorder of the brain caused by mutations in the SLC19A3 gene manifested as early onset progressive encephalopathy that leads to severe disability, ataxia, dystonia, seizures, and death. Early molecular diagnosis and treatment with a lifelong supplementation of high doses of biotin and thiamin improves disease outcome and life expectancy of these patients. We are presenting a 2-year-old girl with subacute dystonia, dysphagia, and ataxia who was diagnosed as a case of biotin-thiamin-responsive basal ganglia disease and showed significant improvement after early initiation of treatment. This case report aimed to show the importance of early diagnosis and treatment initiation based on a high index of suspicion regarding history, neurological signs, and consistent magnetic resonance imaging (MRI) findings.
No takes yet. Share an insight, caveat, or question.
Habiba et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: